AstraZeneca Rises On Report Trump Could Fast-Track Covid-19 Vaccine Candidate
Tiziana Wins Patent Approval For TZLS-501 Potential Covid-19 Treatment
AstraZeneca Receives Russian Nod For Covid-19 Vaccine Trial- Report
Pfizer-BioNTech Covid-19 Candidate Shows ‘Positive’ Data; Analyst Sticks To Hold
Trump Considers Fast-Tracking AstraZeneca Covid Vaccine Ahead Of Elections
Arcturus Inks Deal with Israel For Covid-19 Candidate; Analyst Sees 25% Upside
Gilead Says FDA Could Broaden Remdesivir Use Despite Data; Analyst Slashes PT
Gilead remdesivir study finds only marginal benefit for moderate Covid-19 patients
Sketchy darknet websites are taking advantage of the COVID-19 pandemic – buyer beware
Australia Inks Deal With AstraZeneca For Supply Of Covid-19 Vaccine Candidate
Accelerate Diagnostics Pops 10% On US Emergency Use Nod For Covid-19 Testing
Sorrento Dives 14% In Extended Trading After CFO Ousted
Gilead Sinks After-Hours As FDA Rejects Rheumatoid Arthritis Application
Regeneron, Roche Team Up To Supply Covid-19 Antibody Cocktail To World
AstraZeneca Gets FDA Priority Review For New Dose Of Imfinzi Cancer Drug
Tiziana Spikes 25% In Pre-Market On Patent Win For Foralumab
Krystal Biotech’s ‘Promising’ Cystic Fibrosis Drug Scores Orphan Designation
Gilead 'Very Pleased' With Tango Collab, Boosts Cancer Targets To 15
EU places firm order for AZ/Oxford Uni’s ChAdOx1 COVID-19 vaccine
Once We Have An Approved COVID-19 Vaccine, Then What?
Coronavirus pharma news roundup – 14/08/20
EU Secures 200M Doses Of Johnson & Johnson’s Covid-19 Vaccine Candidate
Quidel’s Lyra Covid-19 Test Gets Nod For Sale In Canada; Shares Rise 6%
Argentina, Mexico To Produce AstraZeneca’s Covid-19 Vaccine Candidate
Covid-19 roundup: Researchers call out Gilead for diversity of remdesivir trials in NEJM; Mexico in vaccine dose, trial talks
Novateur Ventures explores new strategy to reduce hyperinflammatory response caused by COVID-19
Scientists identify hundreds of drug candidates to treat COVID-19
Eli Lilly, Innovent’s TYVYT Expanded Use Application Accepted In China
Mesoblast Tanks 35% Ahead Of FDA Meeting; Analyst Sees 85% Stock Upside
Moderna Spikes 11% On $1.5B US Supply Deal For Covid-19 Vaccine